THOXF (Bioporto AS) Total Long-Term Assets: $1.29 Mil (As of Dec. 2025)


THOXF Bioporto AS THOXF
71 GF Score
Price $0.15
GF Value $0.16
! 3 Warning Signs
View Full Analysis

What is Bioporto AS Total Long-Term Assets?

Bioporto AS THOXF 71 Total Long-Term Assets is $1.29 Mil as of Dec. 2025. GuruFocus rates THOXF with a GF Score™ of 71/100 and a GF Value™ of $0.16. The stock has 3 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Bioporto AS's Total Long-Term Assets for the quarter that ended in Dec. 2025 was $1.29 Mil.

Bioporto AS Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Bioporto AS's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioporto AS Total Long-Term Assets Chart

Bioporto AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.59 1.03 1.10 1.70 1.29

Bioporto AS Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.70 2.28 2.51 2.30 1.29
THOXF
71GF Score
Bioporto AS THOXF
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioporto AS Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $1.29 Mil mean?
Bioporto AS (THOXF) has a Total Long-Term Assets of $1.29 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Bioporto AS and its competitors.
Is Bioporto AS's Total Long-Term Assets too high?
Bioporto AS's current Total Long-Term Assets is $1.29 Mil. Overall, Bioporto AS has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Total Long-Term Assets compare to TMO and DHR?
Bioporto AS's Total Long-Term Assets of $1.29 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Diagnostics & Research company?
A good Total Long-Term Assets depends on the Medical Diagnostics & Research industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Bioporto AS and its competitors. Bioporto AS's current Total Long-Term Assets is $1.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current Total Long-Term Assets of $1.29 Mil. The stock's GF Value™ is $0.16, compared to a current price of $0.15 — trading 6.9% below its estimated fair value. The current Total Long-Term Assets is $1.29 Mil. Bioporto AS's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Bioporto AS (THOXF), the current Total Long-Term Assets is $1.29 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioporto AS (THOXF) Overvalued in 2026?

Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued. The current stock price of $0.15 is trading 6.9% below its estimated GF Value™ of $0.16.

Key valuation signals for THOXF:

  • Total Long-Term Assets: $1.29 Mil
  • GF Value™: $0.16 vs. price of $0.15 (6.9% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioporto AS Business Description

Other Exchanges BIOPOR:Denmark
Address Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
71GF Score

Get the complete analysis for THOXF

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.16
GF Value